恩华药业: 关于董事长增持本公司股票的公告

Core Viewpoint - The chairman of Jiangsu Enhua Pharmaceutical Co., Ltd., Sun Pengsheng, has increased his shareholding in the company, reflecting confidence in the company's future development and performance growth [1][2][3]. Group 1: Shareholding Details - Sun Pengsheng acquired 237,900 shares on June 16, 2025, raising his total holdings to 49,738,538 shares, which represents 4.8713% of the company's total share capital [1][2]. - The actual controllers of the company, including Sun Pengsheng, collectively hold 166,890,250 shares, accounting for 16.4234% of the total share capital prior to the increase [2]. - After the increase, the total shares controlled directly and indirectly by the actual controllers amount to 486,986,571 shares, which is 47.9234% of the total share capital [2]. Group 2: Purpose and Method of Share Purchase - The purpose of the share purchase is based on Sun Pengsheng's firm confidence in the company's growth prospects and a reasonable assessment of the current stock price [3]. - The shares were acquired through the Shenzhen Stock Exchange's trading system via centralized bidding [3]. Group 3: Legal Compliance - The legal opinion from Beijing Lifang Law Firm confirms that Sun Pengsheng meets the qualifications to hold shares in a listed company and that the acquisition complies with relevant laws and regulations [3][4].